Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands

Behavioural Brain Research

Volumn 178, Issue 2, 2007, Pages 274-282

  Hagues, Guillaume ^a   Costentin, Jean ^a   Duterte Boucher, Dominique ^a  

^a CNRS   (France)

Author keywords

Alcohol; Cannabinoids; HU 210; Locomotor activity; Mice; Morphine; Polydrug abuse; Rimonabant

Indexed keywords

ALCOHOL; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; LIGAND; MORPHINE; RIMONABANT;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG ABUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIGHTING REFLEX;

ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; ETHANOL; LIGANDS; MICE; MORPHINE; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; STATISTICS, NONPARAMETRIC; TETRAHYDROCANNABINOL;

EID: 33847410922     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.01.001     Document Type: Article

References (41)

1. Arnold J.C., Topple A.N., Hunt G.E., and McGregor I.S. Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioural sensitization to cocaine. Eur J Pharmacol 354 (1998) 9-16
2. Basavarajappa B.S., and Hungund B.L. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol 40 (2005) 15-24
3. Basavarajappa B.S., Yalamanchili R., Cravatt B.F., Cooper T.B., and Hungund B.L. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology 50 (2006) 834-844
4. Bass C.E., and Martin B.R. Time course for the induction and maintenance of tolerance to Δ-9 tetrahydrocannabinol in mice. Drug Alcohol Depend 60 (2000) 113-119
5. Chaperon F., and Thiébot M.-H. Behavioural effects of cannabinoid agents in animals. Crit Rev Neurobiol 13 (1999) 243-281
6. Colombo G., Agabio R., Mauro F., Guano L., Lobina C., Loche A., et al. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR 141716. Alcohol Acohol 33 (1998) 126-130
7. Colombo G., Serra S., Vacca G., Carai M.A.M., and Gessa G.L. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav 81 (2005) 369-380
8. Degenhardt L., Hall W., and Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 64 (2001) 319-327
9. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85 (1988) 5274-5278
10. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 377-391
11. Dudek B.C., and Phillips T.J. Distinctions among sedative, disinhibitory and ataxic properties of ethanol in inbred and selectively bred mice. Psychopharmacology 101 (1990) 93-99
12. Evans M.A., Harbison R.D., Brown D.J., and Forney R.B. Stimulant actions of Δ-9 tetrahydrocannabinol in mice. Psychopharmacology 50 (1976) 245-250
13. Fattore L., Deiana S., Spano S.M., Cossu G., Fadda P., Sherma M., et al. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 81 (2005) 343-359
14. Ferrari F., Ottani A., and Giuliani D. Influence of the cannabinoid agonist HU 210 on cocaine- and CQP 201-403-induced behavioural effects in rat. Life Sci 65 (1999) 823-831
15. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behaviour. Curr Drug Targets 4 (2005) 633-642
16. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez De Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat Neurosci 2 (1999) 358-363
17. Gonzalez S., Valenti M., De Miguel R., Fernandez-Ruiz J., Di Marzo V., and Ramos J.A. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats and their possible relevance to alcohol relapse. Br J Pharmacol 143 (2004) 455-464
18. Gonzalez S., Cebeira M., and Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboraty animals. Pharmacol Biochem Behav 81 (2005) 300-318
19. Gorriti M.A., Rodriguez De Fonseca F., Navarro M., and Palomo T. Chronic Δ-9 tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365 (1999) 133-142
20. Hattendorf C.H., Hattendorf M., Coper H., and Fernandes M. Interaction between Δ-9 tetrahydrocannabinol and d-amphetamine. Psychopharmacology 54 (1977) 177-182
21. 1 receptor knockout mice exhibit markedly reduced alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 84 (2003) 698-704
22. Little P.J., Compton D.R., Mechoulam R., and Martin B.R. Stereochemical effects of 11-OH-Δ-8-tetrahydrocannabinol-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 32 (1989) 661-666
23. Mailleux P., and Vanderhaeghen J.-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
24. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20 (1999) 287-294
25. Manzanares J., Ortiz S., Oliva J.M., Perez-Rial S., and Palomo T. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects. Alcohol Alcohol 40 (2005) 25-34
26. 1 knockout mice. Eur J Neurosci 12 (2000) 4038-4046
27. 1 receptor knockout mice. Eur J Pharmacol 383 (1999) R1-R3
28. 1 agonist WIN 55,212-2 in Lewis rats. Pharmacol Biochem Behav 73 (2002) 835-842
29. 1 receptor knockout mice. Neuropharmacology 46 (2004) 243-253
30. Norwood C.S., Cornish J.L., Mallet P.E., and McGregor I.S. Pre-exposure to the cannabinoid receptor agonist CP 55,240 enhances morphine behavioural sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 465 (2003) 105-114
31. 1 receptor function alters development of tolerance to alcohol. Alcohol Alcohol 41 (2006) 24-32
32. Ottani A., and Giuliani D. HU 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 7 (2001) 131-145
33. 1) and μ-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
34. 1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144 (1999) 144-150
35. Pryor G.T., Larsen F.F., Husain S., and Braude M.C. Interactions of Δ-9 tetrahydrocannabinol with d-amphetamine, cocaine and nicotine in rats. Pharmacol Biochem Behav 8 (1978) 295-318
36. 1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21 (2001) 823-833
37. Rodriguez de Fonseca F. Role of endogenous cannabinoid system in alcoholism (meeting report). In: Hungund BL, Basavarajappa BS, Vadasz C, Kunos G, Rodriguez de Fonseca F, Colombo G, Serra S, Parsons L, Koob GF. Ethanol, endocannabinoids and the cannabinoidergic signalling system. Alcohol Clin Exp Res 2002;26:565-72.
38. Singh M.E., Verty A.N.A., Price I., McGregor I.S., and Mallet P.E. Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology 47 (2004) 1157-1169
39. 1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19 (1999) 9271-9280
40. Vigano D., Cascio M.G., Rubino T., Fezza F., Vaccani A., Di Marzo V., et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoylglycerol, in rat brain. Neuropsychopharmacology 28 (2003) 1160-1167
41. Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., et al. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909 (2001) 121-126